<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03843658</url>
  </required_header>
  <id_info>
    <org_study_id>R-18002</org_study_id>
    <nct_id>NCT03843658</nct_id>
  </id_info>
  <brief_title>Identifying Novel Biomarkers in Early Rheumatology Patients</brief_title>
  <official_title>Identifying Novel Biomarkers in Early Rheumatology Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arthritis Northwest PLLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Inova Diagnostics Inc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Nebraska</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Arthritis Northwest PLLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients new to a rheumatology practice will be asked if they want to consent to their blood
      sample, medical records, and hand/foot x-rays (with sharp scores) for the analysis and
      correlation with the diagnosis they will receive from the rheumatologist.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At the end of their first visit new rheumatology patients will be asked for their interest in
      joining the Inova biomarker study. If yes, the patient will be consented, blood will be drawn
      for the Inova biomarkers, and x-rays will be sent for sharp scoring. Patients may decline and
      will not be part of the Inova study. Patients who decline will continue to receive standard
      of care treatment henceforth.

      Patients in the Inova trial will receive a diagnosis from their doctor and are placed into
      separate cohorts based upon their diagnosis. The Inova biomarker results of each cohort will
      be cross-correlated with diagnoses, pre-screening tool results. Baseline disease activity and
      sharp scores will also be correlation variables.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 15, 2019</start_date>
  <completion_date type="Anticipated">September 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 15, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The correlation between novel biomarkers and the primary rheumatology diagnosis</measure>
    <time_frame>18 month enrollment period. No follow-up period</time_frame>
    <description>Pearson's correlation coefficient of each biomarker to each cohort</description>
  </primary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Rheumatologic Disorder</condition>
  <arm_group>
    <arm_group_label>Rheumatoid Arthritis</arm_group_label>
    <description>Clinician diagnosed rheumatoid arthritis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Spondyloarthropathy</arm_group_label>
    <description>Ankylosing spondylitis and psoriatic arthritis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crystalline arthritis</arm_group_label>
    <description>Gout and Pseudo gout</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Connective Tissue Disease</arm_group_label>
    <description>Lupus, myositis, scleroderma, and sjogren's</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Inflammatory arthritis</arm_group_label>
    <description>E.g. Osteoarthritis and Fibromyalgia</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>There is no intervention, but a diagnosis.</intervention_name>
    <description>Cohorts will be determined by the primary rheumatology diagnosis.</description>
    <arm_group_label>Connective Tissue Disease</arm_group_label>
    <arm_group_label>Crystalline arthritis</arm_group_label>
    <arm_group_label>Non-Inflammatory arthritis</arm_group_label>
    <arm_group_label>Rheumatoid Arthritis</arm_group_label>
    <arm_group_label>Spondyloarthropathy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All newly referred adults to Arthritis Northwest PLLC will be offered the opportunity to
        enroll in the study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly referred Arthritis Northwest PLLC

          -  Age 18 or older

        Exclusion Criteria:

          -  None.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Terri Cone</last_name>
    <phone>5098386500</phone>
    <email>tcone@arthritisnw.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bonnie Burgess</last_name>
    <phone>5098386500</phone>
    <email>bburgess@arthritisnw.com</email>
  </overall_contact_backup>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 14, 2019</study_first_submitted>
  <study_first_submitted_qc>February 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2019</study_first_posted>
  <last_update_submitted>February 14, 2019</last_update_submitted>
  <last_update_submitted_qc>February 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rheumatic Diseases</mesh_term>
    <mesh_term>Collagen Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

